Loading…
← CockpitCompetitor Analysis › CGEM Cullinan Therapeutics, Inc.Open in the cockpit ↗

Cullinan Therapeutics, Inc.CGEMCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 6
Mkt cap
$585M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$10.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
119 days
17 Mar 2027
Close · USD$9.01
1D-2.9%
1W-20.6%
1M-39.2%
3M-57.9%
6M-37.1%
YTD-12.9%
1Y+2.7%
ATR %12.2%
Beta1.65
52w lowhigh61.1% off high

What Cullinan Therapeutics does

Employees: 109

Cullinan Therapeutics at a glance

Size Cullinan Therapeutics (CGEM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $585M, the 2565th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.01 on 18 Nov 2026.

Performance Over six months the shares fell 37.1%, against -29.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.

Short interest Short interest is 12.3% of the free float (30 Oct 2026).

Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026Peer median 74CGEM 64
Six months, rebased to 100: Cullinan Therapeutics against the median of its 20 peers (local-currency closes).

Cullinan Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$290,000-$311,000-$306,000-$310,000-$93,000
EBITDA-$219M-$241M-$197M-$190M-$132M
Net income-$203M-$220M-$167M-$153M$111M
Free cash flow-$165M-$176M-$145M-$134M-$128M
Capital expenditure$11,000$49,000$0$208,000$1.13M
Total debt$2.00M$2.68M$2.15M$3.59M$5.01M

Quarterly statements and history in the cockpit →

Cullinan Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%6034392157474330014722563613IMMXALMSENTXDBV688356603567002940CGEM6-month return →1-month return →
Up and to the right = strong over both horizons. Cullinan Therapeutics is the large dot.

Cullinan Therapeutics competitors and peer comparison

How Cullinan Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cullinan Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCGEMPeer medianRank in peer set
1-month return-39.2%-11.8%lowest of 20
6-month return-37.1%-29.5%9th lowest of 20
Distance from 52-week high-61.1%-44.1%4th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%20.1×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Alumis ALMSUnited States$569M-80%-67%-5,375%23.9×n/an/a
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%8.7×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%

Questions

Which companies are Cullinan Therapeutics's closest peers?
The cockpit's peer set: GuiZhou SanLi Pharmaceutical (603439.SS), Lepu Biopharma (2157.HK), Oneness Biotech (4743.TWO), Xiangxue Pharmaceutical (300147.SZ), Abbisko Cayman (2256.HK), Beijing Tong Ren Tang Chinese Medicine (3613.HK), Immix Biopharma (IMMX), JIANMIN PHARMACEUTICAL (600976.SS).
How has Cullinan Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -37.1% against -29.5% for the median peer; over one year +2.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.